Search results
1 mar 2016 · This is the first randomized controlled trial that has compared the efficacy and safety of 3% diquafosol ophthalmic solution with 0.1% sodium hyaluronate ophthalmic solution on preexisting dry eye patients who had undergone cataract surgery.
27 kwi 2021 · Diquafosol tetrasodium (DQS), a recently developed ophthalmic solution, has been reported to be effective in DES, but no study evaluated post-cataract surgery lipid layer thickness (LLT) changes...
13 maj 2015 · Diquafosol ophthalmic solution 3 % (Diquas ®) is a P2Y 2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye.
This study aimed to evaluate the efficacy and safety of 3% diquafosol ophthalmic solution in dry eye patients, and to compare its efficacy with that of 0.1% sodium hyaluronate ophthalmic solution as an active control.
Diquafosol ophthalmic solution 3 % (Diquas (®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye.
5 wrz 2018 · Four-week treatment with 3% diquafosol ophthalmic solution significantly improved DE symptoms (p < 0.0001), increased TFBUT (p < 0.0001), and reduced corneoconjunctival staining scores (p < 0.0001). Schirmer I values were not changed by treatment.
Diquafosol ophthalmic solution 3 % (Diquas ) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye.
